Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-07-03
2007-07-03
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000, C530S385000, C530S387100, C530S387700, C530S388100, C424S134100, C424S135100, C424S141100, C424S155100, C424S142100, C424S178100, C424S085100, C435S007900, C435S188000, C435S320100
Reexamination Certificate
active
10461878
ABSTRACT:
This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.
REFERENCES:
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6632926 (2003-10-01), Chen et al.
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2003/0096249 (2003-05-01), Westphal et al.
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 2005/0002945 (2005-01-01), McBride et al.
Price et al (Tumor Biology 1998, 19:1-20).
Gold et al (Int J Cancer, 1994, 57:204-210).
Ho et al (Semin. Oncol. 1997, 2:187-202).
Walker et al (Pharmaceutical Research, 1995, 12:1548-1553).
Gold, et al., “Characterization of Monoclonal Antibody Pam4 Reactive with a Pancreatic Cancer Mucin” Int. J. Cancer: 57, 204-210 (1994) XP-002963400.
Mariani, Giuliano, et al., “Initial Tumor Targeting, Biodistribution, and Pharmacokinetic Evaluation of the Monoclonal Antibody PAM4 in Patients with Pancreatic Cancer” Cancer Resesearch (Suppl. 55. Dec. 1, 1995, pp. 5911s-5915s.
Gold, David V., et al., “Radioimmunotherapy of Experimental Pancreatic Cancer with 1311-Labeled Monoclonal Antibody PAM4” Int. J. Cancer: 71, 660-667 (1997) XP-002258775.
Cardillo, Thomas, et al., “Therapeutic Advantage of 90Yttrium-versus 131Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer” Clinical Cancer Research vol. 7, 3186-3192, Oct. 2001.
Green, M. C., et al., “Monoclonal Antibody Therapy for Solid Tumors” Cancer Treatment Reviews 2000; 26; 269-286 XP009019784.
Price, M. R., et al., “Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin” Tumor Biol 1998; 19(suppl):1-20 XP-002071245.
Gold David V.
Goldenberg David M.
Hansen Hans J.
Faegre & Benson LLP
Helms Larry R.
Immunomedics Inc.
Tungaturthi Parithosh K.
LandOfFree
Monoclonal antibody cPAM4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody cPAM4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody cPAM4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776309